Incretin-based Combination Therapy in Type 2 Diabetes Mellitus
Journal of the Korean Medical Association
;
: 1030-1036, 2009.
Article
Dans Coréen
| WPRIM
| ID: wpr-154386
ABSTRACT
While there are many therapies for type 2 diabetes are available including insulin secretagogues, insulin sensitizers and exogenous insulin, many patients are unable to reach recommended therapeutic targets. Incretin-based therapies have recently been introduced into clinical practice, and these novel therapies may make it possible to achieve improved glycemic control either with no weight gain (dipeptidyl peptidase-4 [DPP-4] inhibitors sitagliptin and vildagliptin, or with weight loss (glucagon-like peptide-1 [GLP-1] mimetics exenatide and liraglutide). This article aims to provide an overview of efficacy and safety data regarding incretinbased clinical trials in type 2 diabetic patients, and propose a systematic approach to treatment including patient selection and optimal treatment combination. In addition, preclinical data suggest that incretin-based therapies may also preserve-cell function. Therefore, these agents hold out promise of a truly disease-modifying therapy that would target the progressive nature of type 2 diabetes. Additional clinical trials will be required to test such hypothesis.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Peptides
/
Pyrazines
/
Pyrrolidines
/
Triazoles
/
Venins
/
Adamantane
/
Prise de poids
/
Perte de poids
/
Sélection de patients
/
Diabète de type 2
Limites du sujet:
Humains
langue:
Coréen
Texte intégral:
Journal of the Korean Medical Association
Année:
2009
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS